Fernandez Juan M, Rodriguez-Pérez José C, Lorenzo-Medina M Mercedes, Rodriguez-Esparragon Fancisco, Quevedo-Reina Juan C, Hernandez-Socorro Carmen R
Medical Manager Southern Europe, Baxter Healthcare Ltd., Madrid 28830, Spain.
Escuela de Doctorado, Universidad De Las Palmas De Gran Canaria, Las Palmas 35001, Canary Islands, Spain.
World J Nephrol. 2025 Mar 25;14(1):99044. doi: 10.5527/wjn.v14.i1.99044.
Equations for estimation glomerular filtration rate (eGFR) have been associated with poor clinical performance and their clinical accuracy and reliability have been called into question.
To assess the longitudinal changes in measured glomerular filtration rate (mGFR) in patients with autosomal dominant polycystic kidney disease (ADPKD).
Analysis of an ambispective data base conducted on consecutive patients diagnosed with ADPKD. The mGFR was assessed by iohexol clearance; while eGFR was calculated by three different formulas: (1) The chronic kidney disease epidemiology collaboration (CKD-EPI); (2) Modification of diet in renal disease (MDRD); and (3) The 24-hour urine creatinine clearance (CrCl). The primary end-points were the mean change in mGFR between the baseline and final visit, as well as the comparison of the mean change in mGFR with the change estimated by the different formulas.
Thirty-seven patients were included in the study. As compared to baseline, month-6 mGFR was significantly decrease by -4.4 mL/minute ± 10.3 mL/minute ( = 0.0132). However, the CKD-EPI, MDRD, and CrCl formulas underestimated this change by 48.3%, 89.0%, and 45.8% respectively, though none of these differences reached statistical significance ( = 0.3647; = 0.0505; and = 0.736, respectively). The discrepancies between measured and estimated glomerular filtration rate values, as evaluated by CKD-EPI ( = 0.29, = 0.086); MDRD ( = 0.19, = 0.272); and CrCl ( = 0.09, = 0.683), were not correlated with baseline mGFR values.
This study indicated that eGFR inaccurately reflects the decline in mGFR and cannot reliably track changes over time. This poses significant challenges for clinical decision-making, particularly in treatment strategies.
估算肾小球滤过率(eGFR)的公式与较差的临床性能相关,其临床准确性和可靠性受到质疑。
评估常染色体显性遗传性多囊肾病(ADPKD)患者实测肾小球滤过率(mGFR)的纵向变化。
对连续诊断为ADPKD的患者进行双向数据库分析。mGFR通过碘海醇清除率评估;而eGFR通过三种不同公式计算:(1)慢性肾脏病流行病学协作组(CKD-EPI)公式;(2)肾脏病饮食改良(MDRD)公式;(3)24小时尿肌酐清除率(CrCl)。主要终点是基线和末次访视之间mGFR的平均变化,以及mGFR的平均变化与不同公式估计变化的比较。
37例患者纳入研究。与基线相比,6个月时mGFR显著下降-4.4毫升/分钟±10.3毫升/分钟(P = 0.0132)。然而,CKD-EPI、MDRD和CrCl公式分别低估了这一变化的48.3%、89.0%和45.8%,尽管这些差异均未达到统计学显著性(分别为P = 0.3647;P = 0.0505;P = 0.736)。通过CKD-EPI(P = 0.29,P = 0.086)、MDRD(P = 0.19,P = 0.272)和CrCl(P = 0.09,P = 0.683)评估的实测和估计肾小球滤过率值之间的差异与基线mGFR值无关。
本研究表明,eGFR不能准确反映mGFR的下降,无法可靠地追踪随时间的变化。这给临床决策带来了重大挑战,尤其是在治疗策略方面。